97 related articles for article (PubMed ID: 9242985)
1. Evidence for a specific interaction of vitronectin with arginine: effects of reducing agents on the expression of functional domains and immunoepitopes.
Seiffert D; Wagner NV
Biochimie; 1997 Apr; 79(4):205-10. PubMed ID: 9242985
[TBL] [Abstract][Full Text] [Related]
2. The glycosaminoglycan binding site governs ligand binding to the somatomedin B domain of vitronectin.
Seiffert D
J Biol Chem; 1997 Apr; 272(15):9971-8. PubMed ID: 9092537
[TBL] [Abstract][Full Text] [Related]
3. Kinetic analysis of the interaction between vitronectin and the urokinase receptor.
Okumura Y; Kamikubo Y; Curriden SA; Wang J; Kiwada T; Futaki S; Kitagawa K; Loskutoff DJ
J Biol Chem; 2002 Mar; 277(11):9395-404. PubMed ID: 11773078
[TBL] [Abstract][Full Text] [Related]
4. The cell adhesion domain in plasma vitronectin is cryptic.
Seiffert D; Smith JW
J Biol Chem; 1997 May; 272(21):13705-10. PubMed ID: 9153222
[TBL] [Abstract][Full Text] [Related]
5. Two functionally distinct pools of vitronectin (Vn) in the blood circulation: identification of a heparin-binding competent population of Vn within platelet alpha-granules.
Seiffert D; Schleef RR
Blood; 1996 Jul; 88(2):552-60. PubMed ID: 8695803
[TBL] [Abstract][Full Text] [Related]
6. Type 1 plasminogen activator inhibitor induces multimerization of plasma vitronectin. A suggested mechanism for the generation of the tissue form of vitronectin in vivo.
Seiffert D; Loskutoff DJ
J Biol Chem; 1996 Nov; 271(47):29644-51. PubMed ID: 8939896
[TBL] [Abstract][Full Text] [Related]
7. A method for defining binding sites involved in protein-protein interactions: analysis of the binding of plasminogen activator inhibitor 1 to the somatomedin domain of vitronectin.
Royle G; Deng G; Seiffert D; Loskutoff DJ
Anal Biochem; 2001 Sep; 296(2):245-53. PubMed ID: 11554720
[TBL] [Abstract][Full Text] [Related]
8. The reduced, denatured somatomedin B domain of vitronectin refolds into a stable, biologically active molecule.
Kamikubo Y; Kroon G; Curriden SA; Dyson HJ; Loskutoff DJ
Biochemistry; 2006 Mar; 45(10):3297-306. PubMed ID: 16519524
[TBL] [Abstract][Full Text] [Related]
9. Vimentin exposed on activated platelets and platelet microparticles localizes vitronectin and plasminogen activator inhibitor complexes on their surface.
Podor TJ; Singh D; Chindemi P; Foulon DM; McKelvie R; Weitz JI; Austin R; Boudreau G; Davies R
J Biol Chem; 2002 Mar; 277(9):7529-39. PubMed ID: 11744725
[TBL] [Abstract][Full Text] [Related]
10. Interaction of plasminogen activator inhibitor type-1 (PAI-1) with vitronectin (Vn): mapping the binding sites on PAI-1 and Vn.
Schroeck F; Arroyo de Prada N; Sperl S; Schmitt M; Viktor M
Biol Chem; 2002; 383(7-8):1143-9. PubMed ID: 12437099
[TBL] [Abstract][Full Text] [Related]
11. The somatomedin B domain of vitronectin. Structural requirements for the binding and stabilization of active type 1 plasminogen activator inhibitor.
Seiffert D; Ciambrone G; Wagner NV; Binder BR; Loskutoff DJ
J Biol Chem; 1994 Jan; 269(4):2659-66. PubMed ID: 7507927
[TBL] [Abstract][Full Text] [Related]
12. Multimeric vitronectin. Identification and characterization of conformation-dependent self-association of the adhesive protein.
Stockmann A; Hess S; Declerck P; Timpl R; Preissner KT
J Biol Chem; 1993 Oct; 268(30):22874-82. PubMed ID: 7693680
[TBL] [Abstract][Full Text] [Related]
13. Evidence that type 1 plasminogen activator inhibitor binds to the somatomedin B domain of vitronectin.
Seiffert D; Loskutoff DJ
J Biol Chem; 1991 Feb; 266(5):2824-30. PubMed ID: 1704366
[TBL] [Abstract][Full Text] [Related]
14. Heparin-binding properties of vitronectin are linked to complex formation as illustrated by in vitro polymerization and binding to the terminal complement complex.
Høgåsen K; Mollnes TE; Harboe M
J Biol Chem; 1992 Nov; 267(32):23076-82. PubMed ID: 1385412
[TBL] [Abstract][Full Text] [Related]
15. Structural and functional analysis of the plasminogen activator inhibitor-1 binding motif in the somatomedin B domain of vitronectin.
Deng G; Royle G; Wang S; Crain K; Loskutoff DJ
J Biol Chem; 1996 May; 271(22):12716-23. PubMed ID: 8662688
[TBL] [Abstract][Full Text] [Related]
16. The composition of complexes between plasminogen activator inhibitor 1, vitronectin and either thrombin or tissue-type plasminogen activator.
van Meijer M; Stoop A; Smilde A; Preissner KT; van Zonneveld AJ; Pannekoek H
Thromb Haemost; 1997 Mar; 77(3):516-21. PubMed ID: 9066004
[TBL] [Abstract][Full Text] [Related]
17. Functional structure of the somatomedin B domain of vitronectin.
Zhou A
Protein Sci; 2007 Jul; 16(7):1502-8. PubMed ID: 17567740
[TBL] [Abstract][Full Text] [Related]
18. Identification of the disulfide bonds in the recombinant somatomedin B domain of human vitronectin.
Kamikubo Y; Okumura Y; Loskutoff DJ
J Biol Chem; 2002 Jul; 277(30):27109-19. PubMed ID: 12019263
[TBL] [Abstract][Full Text] [Related]
19. Cyr61/CCN1 displays high-affinity binding to the somatomedin B(1-44) domain of vitronectin.
Francischetti IM; Kotsyfakis M; Andersen JF; Lukszo J
PLoS One; 2010 Feb; 5(2):e9356. PubMed ID: 20195466
[TBL] [Abstract][Full Text] [Related]
20. Interaction of plasminogen activator inhibitor type-1 (PAI-1) with vitronectin.
Arroyo De Prada N; Schroeck F; Sinner EK; Muehlenweg B; Twellmeyer J; Sperl S; Wilhelm OG; Schmitt M; Magdolen V
Eur J Biochem; 2002 Jan; 269(1):184-92. PubMed ID: 11784312
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
